Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial

Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial

Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) m...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ming Gao, Xia Zhang, Huan Yan, Yan Zhao, Fang Yuan, Decong Sun, Xuejiao Yang, Yanfang Ju, Lijie Wang, Haitao Tao, Luyuan Tian, Changhong Zhao, Junxun Ma, Yi Hu, Zhefeng Liu
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-01-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359241311058
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial
by: Yu-Chun Zhu, et al.
Published: (2024-11-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial
by: Lixia Yi, et al.
Published: (2024-12-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
by: Jian Wang, et al.
Published: (2020-10-01)

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
by: Zhonghua Zhao, et al.
Published: (2024-12-01)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
by: Xin Sun, et al.
Published: (2020-05-01)

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
by: Huimin Zou, et al.
Published: (2025-01-01)

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis
by: Guiyuan Xiang, et al.
Published: (2024-11-01)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Published: (2020-05-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
by: K. Kisielewska, et al.
Published: (2024-01-01)

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
by: Jun Fan, et al.
Published: (2021-11-01)

Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
by: Zhiwei Zheng, et al.
Published: (2024-12-01)

Correction: Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
Published: (2022-02-01)

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
by: Ying Cheng, et al.
Published: (2025-02-01)

Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center
by: Jin-Xing Zhang, et al.
Published: (2022-01-01)

Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication
by: Mei Wang, et al.
Published: (2020-05-01)

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study
by: Jian Zhang, et al.
Published: (2024-11-01)

Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review
by: Man Sun, et al.
Published: (2025-01-01)

Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated NSCLC
by: Junzhu Xu, et al.
Published: (2024-12-01)

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
by: Koichi Takayama, et al.
Published: (2016-01-01)

Camrelizumab-Related Lethal Arrhythmias and Myasthenic Crisis in a Patient with Metastatic Thymoma
by: Bo Zhang, et al.
Published: (2022-01-01)

Eosinophilic Gastritis in a Patient Previously Treated with Dupilumab
by: Masaya Iwamuro, et al.
Published: (2020-01-01)

Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis
by: Xiaodong Mi, et al.
Published: (2024-12-01)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
by: Celeste Lebbe, et al.
Published: (2020-05-01)

Prospective multicenter study of camrelizumab in real-world settings for asian patients with esophageal squamous cell carcinoma
by: Tingting Li, et al.
Published: (2024-11-01)

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
by: Hang A, et al.
Published: (2024-12-01)

Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment
by: Bi Sheng MD, et al.
Published: (2025-01-01)

Measles Outbreak among Previously Immunized Adult Healthcare Workers, China, 2015
by: Zhengyi Zhang, et al.
Published: (2016-01-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
by: Xiaohui Zeng, et al.
Published: (2019-12-01)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
by: Qiang Liu, et al.
Published: (2020-05-01)

Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases
by: Liqun Li, et al.
Published: (2024-12-01)

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial
by: Yaoping Shi, et al.
Published: (2024-12-01)

Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
by: Yurou Chu, et al.
Published: (2025-02-01)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
by: Jean-Charles Soria, et al.
Published: (2020-10-01)

Sciatic nerve injury treated by acupuncture: a bibliometric study and visualization analysis
by: Yan Wang, et al.
Published: (2024-12-01)

Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01)

Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma
by: Alexandrina Balanean, et al.
Published: (2024-12-01)

Synchronized autologous T-cell immunotherapy with hyperthermia to previously heavy treated advanced renal cell carcinoma
by: Jun Ren, et al.
Published: (2024-12-01)

Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC
by: Jacqueline V. Aredo, MD, MS, et al.
Published: (2024-12-01)